Here's what the filings actually say: Lilly spent 2025 turning a single blockbuster idea into a patent estate. The grants aren't one invention restated — they're a methodical broadening of claims across the incretin class.

Incretins are the gut hormones, GIP and GLP-1, that govern blood sugar and appetite. Lilly's lead drug acts on both. The 2025 record shows the company patenting around that dual mechanism repeatedly. Grant US12252524B2 covers GIP/GLP-1 co-agonist compounds, with claims reaching into formulation and dosing.

“The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors.”— U.S. Patent No. 12,252,524 source

Two more grants extend the same idea. US12295987B2 covers a method of using a GIP/GLP1 co-agonist for diabetes, and US12365716B2 covers incretin analogs and their uses. Same inventors recur across them — this is one program filing in waves.

Why file so many overlapping claims? Because a franchise this valuable can't rest on a single patent with a single expiry. By covering the compound, the method of use, the analogs, and the formulation separately, a company forces any challenger to clear every live claim — and staggers the dates so the protected core keeps moving forward.

The crosswalk worth keeping: when you see a wave of grants to one company on one mechanism in one year, you're watching a moat being dug, not a new discovery. Lilly's 2025 incretin grants are a defensive roadmap for the drug class it leads.

The honest caveat is that a thick estate slows challengers but doesn't stop the underlying science. Competitors are filing on the same dual- and triple-agonist territory. The 2025 grants tell you Lilly intends to defend the franchise aggressively — they don't tell you the competition won't eventually route around it.